Proud to have represented Artofin in QIAGEN’s $80m acquisition of Genoox

We are pleased to have represented Artofin Venture Capital Fund, an investor in Genoox, in the company’s recent acquisition by global diagnostics giant QIAGEN for $80 million.

The acquisition underscores the great opportunities emerging in the field of precision medicine – and represents a successful outcome for Artofin, which recognized the potential.

Adv. Amit Hirsch represented Artofin in the transaction; Advs. Erez Mizrachi, and Amit Hirsch also regularly represent Artofin in their investments.

Congrats to Eitan Lavie David Meyohas and the entire Artofin team. Here’s to many more exits!

For the full coverage in Globes, click here>>